Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Surveys and Questionnaires 5Pemetrexed 3Paclitaxel 3Gemcitabine 3Docetaxel 3Brachytherapy 3pembrolizumab 2Topotecan 2Saline Solution 2Radiotherapy 2Radiation 2FANG vaccine 2Everolimus 2Doxorubicin 2Cisplatin 2Carboplatin 2CP protocol 2temsirolimus 1selinexor 1osimertinib 1niraparib 1fosaprepitant 1ferumoxtran-10 1ferrous fumarate 1durvalumab 1cobimetinib 1atezolizumab 1alovudine 1Vitamin D 1Uterine Artery Embolization 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Uterine Neoplasms × OSI 930 × Clear all
NCT00513851 2011-09-27

Phase 1 Study of OSI-930 in Cancer Patients

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡